skip to Main Content

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows
Patients with TP53-mutated pancreatic ductal adenocarcinoma, or PDAC, may respond better to adjuvant treatment with the chemotherapy drug gemcitabine (Gemzar) than patients with TP53-wildtype tumors, according to a new study published in Clinical Cancer Research.

Although the study’s authors noted that their findings will need to be validated through further research, the potential for TP53 to serve as a predictive and prognostic biomarker for PDAC indicates the rise of precision medicine in a patient population that has previously seen limited treatment advances. Read more . . . 


Back To Top